| [1] |
Loomba R, Sanyal AJ. The gobal NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013,10:686-690.
|
| [2] |
Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28:11-17.
|
| [3] |
Karlas T,Wiegand J,Berg T.Gastrointestinal complications of obesity: non-alcoholic fatty liver disease(NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab, 2013, 27:195-208.
|
| [4] |
Eguchi Y,Hyogo H,Ono M,et al.Prevalence and associated metabolic factors of nonalcoholic fatty liver disea s e in the general population from 2009 to 2010 in Japan:a m ulticenter large retrospective study.J G astroenterol,2012,47:586 -595.
|
| [5] |
Lambert JE,Ramos-Roman MA, Browning JD,Parks EJ.Increased de Novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.Gastroenterology, 2014,146:726-735.
|
| [6] |
杜娟,潘红艳,林立美,等.黄酮和维生素E对己烯雌酚所致雄性小鼠肝脏氧化损伤的保护作用.中国畜牧兽医,2013,40:149-153.
|
| [7] |
Sanyal AJ, Chalasani N,Kowdley KV,et al.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis.N Engl J Med, 2010,362:1675-1685.
|
| [8] |
Lavine JE,Schwimmer JB,Van Natta ML,et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.JAMA, 2011, 305:1659-1668.
|
| [9] |
Tangen CM, Goodman PJ, Till C, et al.Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials. J Clin Oncol, 2016,34:4338-4344.
|
| [10] |
Barreyro FJ, Holod S, Finocchietto PV, et al.The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int, 2015,35:953-966.
|
| [11] |
Saiman Y,Friedman SL.The role of chemokines in acute liver injury.Front Physiol.2012,3:213.
|
| [12] |
Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for nonalcoholic fatty liver disease. Gut,2017,66: 180-190.
|
| [13] |
李泉,吴彦,胡渠.双环醇联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的疗效分析.检验医学与临床,2014,11:3477-3478.
|
| [14] |
曾静波,庄晓明,穆君.二甲双胍联合吡格列酮对初发 2型糖尿病并发非酒精性脂肪肝的疗效及对血清 Vaspin水平的影响.河北医科大学学报,2015,36:509-512.
|
| [15] |
Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation, 2007, 115:518-533.
|
| [16] |
毕婉蓉,张玉臣,许树长.盐酸吡格列酮治疗非酒精性脂肪肝的疗效分析.同济大学学报,2009,30:111-118.
|
| [17] |
赵胜乾.罗格列酮联合维生素E治疗非酒精性脂肪肝的疗效观察.实用医学杂志,2015,32:43-44.
|
| [18] |
Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016,150:1147-1159.
|
| [19] |
Porez G, Prawitt J, Gross B, et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res,2012,53:1723-1737.
|
| [20] |
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, 2015,385:956-965.
|
| [21] |
Luo J, Ko B,To C, et al. Treatment with Ngm282 significantly improves liver histopathology in a mouse model of non-alcoholic steatohepatitis (Nash).J Hepatol,2015,62:S694.
|
| [22] |
Lounis MA, Escoula Q, Veillette C, et al. SCD1 deficiency protects mice against ethanol-induced liver injury. Biochim Biophys Acta, 2016,1861:1662-1670.
|
| [23] |
Safadi R, Konikoff FM, Mahamid M, et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2014,12:2085-2091.
|
| [24] |
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol, 2015,63:705-712.
|
| [25] |
Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol, 2015,21:7860-7868.
|
| [26] |
Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther, 2013,37:234-242.
|
| [27] |
Armstrong MJ, Gaunt P, Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre,double-blind, randomised, placebo-controlled phase 2 study.Lancet, 2016,387:679-690.
|
| [28] |
杨帆,李钶,蒋晓岚,等. 利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪沉积的影响研究.重庆医学, 2016,45:3493-3495.
|
| [29] |
杨林辉,蔡俊,陈东风.非酒精性脂肪性肝炎患者肠道菌群的变化及意义.临床肝胆病杂志,2012,28:124-126.
|
| [30] |
卢丹,龚大范,廖惠充,等. 双歧杆菌四联活菌治疗非酒精性脂肪肝的疗效观察.广东医学,2016,37:1221-1222.
|
| [31] |
Shirakami Y, Shimizu M, Kubota M, et al. Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis. Eur J Cancer Prev, 2016,25:206-215.
|
